These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37673061)

  • 21. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
    Nauck MA; D'Alessio DA
    Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme).
    Kiyosue A; Dunn JP; Cui X; Hickey A; Hirase T; Imaoka T; Heine RJ
    Diabetes Obes Metab; 2023 Apr; 25(4):1056-1067. PubMed ID: 36545807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).
    Yabe D; Kawamori D; Seino Y; Oura T; Takeuchi M
    Diabetes Obes Metab; 2023 Feb; 25(2):398-406. PubMed ID: 36184780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program.
    Nicholls SJ; Tofé S; le Roux CW; D'Alessio DA; Wiese RJ; Pavo I; Brown K; Weerakkody GJ; Zeytinoglu M; Romera IC
    Cardiovasc Diabetol; 2024 Feb; 23(1):63. PubMed ID: 38341541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates.
    Reitzel SB; Bøgelund M; Basse A; Barszczewska O; Ren H
    Curr Med Res Opin; 2023 Aug; 39(8):1055-1060. PubMed ID: 37415503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States.
    Mody RR; Meyer KL; Ward JM; O'Day KB
    Diabetes Ther; 2023 Dec; 14(12):2045-2055. PubMed ID: 37770706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.
    Vadher K; Patel H; Mody R; Levine JA; Hoog M; Cheng AY; Pantalone KM; Sapin H
    Diabetes Obes Metab; 2022 Sep; 24(9):1861-1868. PubMed ID: 35589616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist.
    Tall Bull S; Nuffer W; Trujillo JM
    J Diabetes Complications; 2022 Dec; 36(12):108332. PubMed ID: 36375235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
    Boye KS; Thieu VT; Sapin H; Lee CJ; Landó LF; Brown K; Bray R; Wiese RJ; Patel H; Rodríguez Á; Yu M
    Diabetes Ther; 2023 Nov; 14(11):1833-1852. PubMed ID: 37526908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.
    Pirro V; Roth KD; Lin Y; Willency JA; Milligan PL; Wilson JM; Ruotolo G; Haupt A; Newgard CB; Duffin KL
    J Clin Endocrinol Metab; 2022 Jan; 107(2):363-378. PubMed ID: 34608929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
    Frias JP; Nauck MA; Van J; Benson C; Bray R; Cui X; Milicevic Z; Urva S; Haupt A; Robins DA
    Diabetes Obes Metab; 2020 Jun; 22(6):938-946. PubMed ID: 31984598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.
    Yu D; Shen S; Zhang J; Wang Q
    Clin Ther; 2023 Aug; 45(8):787-796. PubMed ID: 37455226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.
    Kadowaki T; Chin R; Ozeki A; Imaoka T; Ogawa Y
    Lancet Diabetes Endocrinol; 2022 Sep; 10(9):634-644. PubMed ID: 35914542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials.
    Bhagavathula AS; Vidyasagar K; Tesfaye W
    Pharmaceuticals (Basel); 2021 Sep; 14(10):. PubMed ID: 34681215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial.
    Gao L; Lee BW; Chawla M; Kim J; Huo L; Du L; Huang Y; Ji L
    Nat Med; 2023 Jun; 29(6):1500-1510. PubMed ID: 37231074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis.
    Yang XY; Yin S; Yu YF; Hu G; Hang FZ; Zhou ML; Liu P; Jian WX
    Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7164-7179. PubMed ID: 37606127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
    Thomas MK; Nikooienejad A; Bray R; Cui X; Wilson J; Duffin K; Milicevic Z; Haupt A; Robins DA
    J Clin Endocrinol Metab; 2021 Jan; 106(2):388-396. PubMed ID: 33236115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.